Association of out-of-pocket costs on adherence to common neurologic medications

Neurology. 2020 Mar 31;94(13):e1415-e1426. doi: 10.1212/WNL.0000000000009039. Epub 2020 Feb 19.

Abstract

Objective: To determine the association between out-of-pocket costs and medication adherence in 3 common neurologic diseases.

Methods: Utilizing privately insured claims from 2001 to 2016, we identified patients with incident neuropathy, dementia, or Parkinson disease (PD). We selected patients who were prescribed medications with similar efficacy and tolerability, but differential out-of-pocket costs (neuropathy with gabapentinoids or mixed serotonin/norepinephrine reuptake inhibitors [SNRIs], dementia with cholinesterase inhibitors, PD with dopamine agonists). Medication adherence was defined as the number of days supplied in the first 6 months. Instrumental variable analysis was used to estimate the association of out-of-pocket costs and other patient factors on medication adherence.

Results: We identified 52,249 patients with neuropathy on gabapentinoids, 5,246 patients with neuropathy on SNRIs, 19,820 patients with dementia on cholinesterase inhibitors, and 3,130 patients with PD on dopamine agonists. Increasing out-of-pocket costs by $50 was associated with significantly lower medication adherence for patients with neuropathy on gabapentinoids (adjusted incidence rate ratio [IRR] 0.91, 0.89-0.93) and dementia (adjusted IRR 0.88, 0.86-0.91). Increased out-of-pocket costs for patients with neuropathy on SNRIs (adjusted IRR 0.97, 0.88-1.08) and patients with PD (adjusted IRR 0.90, 0.81-1.00) were not significantly associated with medication adherence. Minority populations had lower adherence with gabapentinoids and cholinesterase inhibitors compared to white patients.

Conclusions: Higher out-of-pocket costs were associated with lower medication adherence in 3 common neurologic conditions. When prescribing medications, physicians should consider these costs in order to increase adherence, especially as out-of-pocket costs continue to rise. Racial/ethnic disparities were also observed; therefore, minority populations should receive additional focus in future intervention efforts to improve adherence.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antiparkinson Agents / economics
  • Cholinesterase Inhibitors / economics
  • Dementia / drug therapy*
  • Excitatory Amino Acid Antagonists / economics
  • Female
  • Gabapentin / economics
  • Health Expenditures*
  • Humans
  • Male
  • Medication Adherence*
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Peripheral Nervous System Diseases / drug therapy*
  • Serotonin Uptake Inhibitors / economics

Substances

  • Antiparkinson Agents
  • Cholinesterase Inhibitors
  • Excitatory Amino Acid Antagonists
  • Serotonin Uptake Inhibitors
  • Gabapentin